Subject
Pulmonary and Respiratory Medicine,Oncology
Reference10 articles.
1. Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-Lung 3 part 2 trial;Makharadze;J Thorac Oncol,2023
2. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial;Gogishvili;Nat Med,2022
3. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial;Sezer;Lancet,2021
4. Resistance to chemoimmunotherapy in non-small-cell lung cancer;Hochmair;Cancer Drug Resist,2020
5. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC;Chang;Lung Cancer,2011